EGQ0.F INOVIQ LTD.
- Market cap
- EUR 10.2M
- P/E
- -
- P/B
- 0.88x
- ROE
- -39.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is EGQ0.F undervalued?
Graham numberThe Graham number of INOVIQ LTD. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INOVIQ LTD. fundamental analysis
No fundamental analysis for INOVIQ LTD. yet.
INOVIQ LTD. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INOVIQ LTD.
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasiv…
Full company profileINOVIQ LTD. financial statements
INOVIQ LTD. annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 468K | 277K | 398K | 535K | 432K |
| Gross Profit | 404K | 220K | 354K | 454K | 355K |
| Operating Income | -7.04M | -9.00M | -10.5M | -7.84M | -9.61M |
| EBITDA | - | -7.04M | -9.32M | -6.63M | -8.34M |
| Net Income | -12.4M | -18.2M | -8.97M | -6.55M | -7.51M |
| EPS | -0.15 | -0.20 | -0.10 | -0.06 | -0.05 |
| Balance Sheet | |||||
| Total Assets | 48.3M | 30.8M | 21.5M | 21.7M | 20.5M |
| Total Liabilities | 5.10M | 2.49M | 1.89M | 1.72M | 1.56M |
| Shareholders' Equity | 27.8M | 28.3M | 19.6M | 20.0M | 18.9M |
| Cash & Short-term Investments | 9.02M | 15.4M | 7.81M | 9.23M | 9.35M |
| Cash Flow | |||||
| Capital Expenditure | 786K | 412K | 292K | 174K | 168K |
| Free Cash Flow | -6.05M | -6.47M | -7.32M | -4.50M | -6.55M |
| Ratios | |||||
| ROE | -44.4% | -64.3% | -45.7% | -32.8% | -39.7% |
| ROA | -25.6% | -59.1% | -41.7% | -30.2% | -36.7% |
| Net Profit Margin | -2,642.0% | -6,575.0% | -2,252.5% | -1,224.8% | -1,737.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INOVIQ LTD. dividends
INOVIQ LTD. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:30 on Dec 1, 2020.
Who owns INOVIQ LTD.
- Insiders 33.95%
- Institutions 7.00%
- Public & others 59.05%
- Shares outstanding 141M
- Free float 117M
INOVIQ LTD. company profile
- Company name
- INOVIQ LTD.
- Ticker
- EGQ0.F
- ISIN
- AU0000196149
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- June
- Address
- 23 Normanby Road, Notting Hill, VIC, Australia, 3168
- Phone
- 61 3 9548 7586
- Website
- inoviq.com
About INOVIQ LTD.
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
INOVIQ LTD. management
4- Dr. Leearne Maree Hinch B.Sc., B.V.M.S., M.B.A., M.R.C.V.S.Chief Executive Officer
- Mr. Mark Edwards BACC, C.A.CFO & Company Secretary
- Dr. Rebecca Lim B.Sc., Ph.D.Chief Scientific Officer
- Dr. Emma Ball B.Sc., M.B.A., Ph.D.Chief Commercial Officer